Amgen 
Welcome,         Profile    Billing    Logout  
 160 Products   813 Diseases   160 Products   1552 Trials   75151 News 


«12...3233343536373839404142...858859»
  • ||||||||||  Tezspire (tezepelumab-ekko) / AstraZeneca, Amgen
    Trial completion date, Trial primary completion date, HEOR, Real-world evidence, Real-world:  ASCENT: A Study for Observing Severe Asthma in Patients Treated With Tezepelumab (clinicaltrials.gov) -  Sep 19, 2024   
    P=N/A,  N=550, Recruiting, 
    Trial completion date: Nov 2025 --> Mar 2026 | Trial primary completion date: Nov 2025 --> Mar 2026
  • ||||||||||  Prolia (denosumab) / Amgen
    Enrollment closed:  PREFERRED-1: PRevEnting FracturEs in REnal Disease 1 (clinicaltrials.gov) -  Sep 19, 2024   
    P4,  N=60, Active, not recruiting, 
    Approved on December 19, 2023. Recruiting --> Active, not recruiting
  • ||||||||||  chlorpromazine / Generic mfg.
    A RARE CASE OF CHLORPROMAZINE-INDUCED IMMUNE HEMOLYTIC ANEMIA (Convention Center Exhibit Hall: Poster Area 2) -  Sep 19, 2024 - Abstract #CHEST2024CHEST_7313;    
    The hematologist was consulted immediately, and the patient received one dose of IV Epoetin alfa 20000 units, one dose of IV Venofer 200 mg and she was also started on IV methylprednisolone 80 mg...The patient's home medications included Chlorpromazine, Divalproex, and Fluoxetine...He was discharged to home with prednisone and divalproex...Cephalosporins, nonsteroidal anti-inflammatory agents, levofloxacin, oxaliplatin, and teicoplanin have been reported to cause IHA... Chlorpromazine is a widely used drug in psychiatry and physicians should be aware of this rare adverse event of hemolytic anemia.
  • ||||||||||  Zarxio (filgrastim-sndz) / Sandoz
    Trial completion:  SMART: Non-interventional, Long-term Safety Data Collection of Zarzio (clinicaltrials.gov) -  Sep 19, 2024   
    P=N/A,  N=245, Completed, 
    Trial completion date: Dec 2025 --> Jun 2027 | Trial primary completion date: Dec 2024 --> Jun 2026 Active, not recruiting --> Completed
  • ||||||||||  Imlygic (talimogene laherparepvec) / Amgen, Opdivo (nivolumab) / BMS, Yervoy (ipilimumab) / BMS
    Journal:  Access to melanoma drugs in Spain: a cross-sectional survey. (Pubmed Central) -  Sep 18, 2024   
    Phase classification: P1/2 --> P2 | Trial completion date: Feb 2025 --> Oct 2025 For most indications that reimbursement is restricted out of the EMA indication, a great diversity on access was found throughout the different hospitals in Spain, including heterogeneity intra-AACC.
  • ||||||||||  Remicade (infliximab) / J&J, Blincyto (blinatumomab) / Astellas, Amgen, Rituxan (rituximab) / Roche
    Journal, IO biomarker:  Deciphering Molecular Mechanisms of Cutaneous Leishmaniasis, Pathogenesis and Drug Repurposing through Systems Biology. (Pubmed Central) -  Sep 18, 2024   
    The drug repurposing results identified cyclosporine, rituximab, infliximab, blinatumomab, and methylprednisolone as candidates for treatment of CL. After validating our model with available experimental data, we found that critical molecules and drug candidates play a crucial role in the treatment of skin lesions caused by Leishmania in prospective studies.
  • ||||||||||  Ibrance (palbociclib) / Pfizer
    Journal, Metastases:  From Breast to Orbit: A Case Report of Metastatic Breast Cancer With Orbital Involvement. (Pubmed Central) -  Sep 17, 2024   
    Systemic treatment was started with hormonal therapy fulvestrant and luteinizing hormone-releasing hormone (LHRH), leuprolide, accompanied by palbociclib. As the incidence of ocular metastasis from breast cancer increases, oncologists need to be vigilant about symptoms and use appropriate diagnostic techniques.
  • ||||||||||  Nplate (romiplostim) / Amgen, Trulicity (dulaglutide) / Eli Lilly
    Review, Journal:  Peptibodies: Bridging the gap between peptides and antibodies. (Pubmed Central) -  Sep 17, 2024   
    Romiplostim and Dulaglutide are the only ones approved by the EMA and FDA, respectively. Given the growing significance of peptibodies in the pharmaceutical landscape, this investigation aims to explain key aspects encompassing the intrinsic properties of peptides, the intricacies of peptibody production, and their potential therapeutic applications.
  • ||||||||||  Vectibix (panitumumab) / Amgen
    Confronting Dual Fronts: Management of Lupus Nephritis, Advanced Colon Cancer, and Nephrotoxicity in the Emergence of Nephro-Oncology (Exhibition area) -  Sep 17, 2024 - Abstract #ESMOAsia2024ESMO_Asia_1094;    
    Case summary We present the case of a 42-year-old woman with a long-standing history of SLE and Class III lupus nephritis, who achieved remission with cyclophosphamide but developed CKD (baseline creatinine clearance 40 mL/min)...The treatment intent was palliative, initiating FOLFOX chemotherapy with a 25% oxaliplatin dose reduction and standard anti-emetic premedication...Molecular testing revealed KRAS wild type, allowing a switch to 5-FU chemotherapy combined with the anti-EGFR agent panitumumab...Standard chemotherapy with moderate emetogenic potential posed significant challenges, impacting renal function. A personalized approach and a deeper understanding of nephro-oncology are warranted to optimize treatment in such patients.
  • ||||||||||  cyclophosphamide / Generic mfg., paclitaxel / Generic mfg., doxorubicin hydrochloride / Generic mfg.
    Shorter duration of primary prophylaxis filgrastim for 4AC-4T dose dense in early breast cancer in resource-limited settings (Exhibition area) -  Sep 17, 2024 - Abstract #ESMOAsia2024ESMO_Asia_862;    
    Conclusions This shorter duration of primary prophylaxis filgrastim allowed most patients to underwent 4AC-4T dose dense regimen without complications, which could reduce cost and side effects of G-CSF, but a closer monitoring should be given after AC. There should be larger randomized study to further evaluate the effectiveness of this schedule, especially in resource limited settings.
  • ||||||||||  Stivarga (regorafenib) / Bayer
    The role of regorafenib for metastatic colorectal cancer in the new era of later-line treatment: Results of the OSERO study (Exhibition area) -  Sep 17, 2024 - Abstract #ESMOAsia2024ESMO_Asia_433;    
    Grade ?3 adverse events (AEs) with a frequency of ?10% were hand-foot syndrome (14.9%), proteinuria (12.3%), and hypertension (11.0%) in Group A, and neutropenia (40.5%) and anemia (12.1%) in Group B. Conclusions REG before or after FTD/TPI plus BEV may contribute to prolong survival in mCRC. Therefore, it would be better to select the sequence of later-line treatment based on the difference of AE profiles.
  • ||||||||||  Ibrance (palbociclib) / Pfizer, Kisqali (ribociclib) / Novartis
    Palbociclib versus ribociclib in first-line therapy of patients with metastatic breast cancer: Direct comparison in real-world practice (Exhibition area) -  Sep 17, 2024 - Abstract #ESMOAsia2024ESMO_Asia_419;    
    The difference in PFS of palbo versus ribo was observed neither in the subgroup of pts with liver metastases (mPFS were 16 months and 20 months, respectively, HR=0.88, 95% CI 0.4-1.9) nor in pts with primary endocrine resistance (mPFS were 9 and 15 months, respectively, HR 1.83, 95% CI 0.7-4.5). Conclusions In real-world practice ribo and palbo demonstrate comparable efficacy both in total population and in subgroups with especially poor prognosis.
  • ||||||||||  Vectibix (panitumumab) / Amgen, Lumakras (sotorasib) / Amgen
    Sotorasib (soto), panitumumab (pani), and FOLFIRI in first-line (1L) KRAS G12C (Hall 404) -  Sep 17, 2024 - Abstract #ESMOAsia2024ESMO_Asia_215;    
    P1, P3
    Conclusions The combination of soto, pani, and FOLFIRI in the 1L setting had a tolerable safety profile and a promising response rate in pts from Japan and ROW. The phase III CodeBreaK 301 (NCT06252649) study is currently enrolling to evaluate this combination against standard of care in 1L mCRC.
  • ||||||||||  umibecestat (CNP520) / Novartis, Amgen, Banner Alzheimer's Institute
    Journal:  Unravelling the Untapped Pharmacological Potential of Plant Molecules as Inhibitors of BACE1: In Silico Explorations for Alzheimer's Disease. (Pubmed Central) -  Sep 15, 2024   
    In the absorption and distribution assessment, these phytochemicals showed significantly better values than the inhibitors CNP520...In both the molecular docking and ADMET assessments, these natural chemicals have shown optimism as potential drug candidates for Alzheimer's disease. However, in order to understand the detailed biological metabolism of these compounds in AD, they need to be evaluated in in vivo studies to validate its efficacy.
  • ||||||||||  Stivarga (regorafenib) / Bayer, Lenvima (lenvatinib) / Eisai, Merck (MSD)
    Journal:  Drug Repurposing Approach to Identify Candidate Drug Molecules for Hepatocellular Carcinoma. (Pubmed Central) -  Sep 14, 2024   
    In conclusion, we identified small molecules that can be further exploited experimentally in HCC therapeutics. Our study also demonstrated the use of the MDeePred deep learning tool in in silico drug repurposing efforts for cancer therapeutics.
  • ||||||||||  Nplate (romiplostim) / Amgen, Doptelet (avatrombopag) / SOBI, Promacta (eltrombopag) / Novartis
    Review, Journal:  Tapering and Sustained Remission of Thrombopoietin Receptor Agonists (TPO-RAs): Is it Time for Paediatric ITP? (Pubmed Central) -  Sep 14, 2024   
    The issue of tapering and discontinuation of TPO-RAs in paediatric patients with ITP has received little attention to date. Given that paediatric ITP has much higher rates of spontaneous remission than ITP in adults, we consider that the possibility of SROT of TPO-RAs in paediatric patients with ITP is a neglected but very relevant issue in this subtype of the disease.
  • ||||||||||  Praluent (alirocumab) / Sanofi, Regeneron, Repatha (evolocumab) / Amgen, Astellas
    Review, Journal:  PCSK9 and Coronary Artery Plaque-New Opportunity or Red Herring? (Pubmed Central) -  Sep 12, 2024   
    Similarly, the PACMAN-AMI study concluded that the qualitative and quantitative changes in coronary plaque were associated with the levels of LDLc. Assessing the severity of coronary artery stenosis and the extent of atherosclerotic burden by means of imaging techniques (e.g., IVUS, OCT and near-infrared spectroscopic) have significantly advanced our understanding of the benefits from promoting plaque regression and achieving to features of plaque stabilization through increasingly intensive lipid-lowering strategies.
  • ||||||||||  TPOXX (tecovirimat) / SIGA Technologies
    Journal:  Supervised screening of Tecovirimat-like compounds as potential inhibitors for the monkeypox virus E8L protein. (Pubmed Central) -  Sep 12, 2024   
    As a result, we have shortlisted five drugs named ABX-1431, Alflutinib, Avacopan, Caspitant, and Darapalib that effectively engage the MPXV surface binding protein. Furthermore, the affinity of the proposed drugs is relatively higher than the Tecovirimat by having higher docking scores, establishing more hydrogen and hydrophobic bonds, engaging key residues in the target's structure, and exhibiting stable molecular dynamics.Communicated by Ramaswamy H. Sarma.